Adidas stock – Adidas Tennis Hu http://adidastennishu.com/ Wed, 23 Nov 2022 19:34:25 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://adidastennishu.com/wp-content/uploads/2021/07/icon-2021-07-08T153415.691.png Adidas stock – Adidas Tennis Hu http://adidastennishu.com/ 32 32 Global Cardiomyopathy Market Report to 2031 – Featuring AstraZeneca, Merck, Novartis, Sanofi, and Abbott, Among Others – ResearchAndMarkets.com https://adidastennishu.com/global-cardiomyopathy-market-report-to-2031-featuring-astrazeneca-merck-novartis-sanofi-and-abbott-among-others-researchandmarkets-com/ Wed, 23 Nov 2022 17:24:00 +0000 https://adidastennishu.com/global-cardiomyopathy-market-report-to-2031-featuring-astrazeneca-merck-novartis-sanofi-and-abbott-among-others-researchandmarkets-com/ DUBLIN–(BUSINESS WIRE)–The “Cardiomyopathy Market Size and Trends Report, including epidemiology and pipeline analysis, competitor assessment, unmet needs, clinical trial strategies and forecasts, 2021-2031″ has been added to drug pipelines from ResearchAndMarkets.com offer. The publisher forecasts the cardiomyopathy therapeutics market within 7MM to grow from $1.6 billion in 2021 at a compound annual growth rate (CAGR) […]]]>

DUBLIN–(BUSINESS WIRE)–The “Cardiomyopathy Market Size and Trends Report, including epidemiology and pipeline analysis, competitor assessment, unmet needs, clinical trial strategies and forecasts, 2021-2031″ has been added to drug pipelines from ResearchAndMarkets.com offer.

The publisher forecasts the cardiomyopathy therapeutics market within 7MM to grow from $1.6 billion in 2021 at a compound annual growth rate (CAGR) of 12.4% to $5.2 billion by 2031 .

Companies cited

  • Astra Zeneca

  • Merck

  • Boehringer Ingelheim

  • Novartis

  • Sanofi

  • Abbott

  • GlaxoSmithKline

  • Bristol Myers Squibb

  • MyoKardie

  • Pfizer

  • Cytokinetics

Main growth drivers:

  • Launch of Camzyos (Bristol Myers Squibb) and aficamten (Cytokinetics) on the 7MM

  • Expanded Entresto (sacubitril + valsartan) label to include CM

Highlights

  • The cardiomyopathy market is currently highly generic and contains many off-label drugs, which provide affordable options with limited side effects. These factors create a rigid barrier for entry of new therapies, but the therapies in the pipeline will be successful due to their strong efficacy and safety profiles and the fact that they are cardiomyopathy-specific therapies. , rather than general cardiovascular drugs.

  • There is a growing emphasis on genetic screening and the development of genetic therapies, as cardiomyopathies are often inherited rather than acquired. Emprumapimod will be the first commercially available gene therapy, as it targets patients with DCM due to a mutation in the lamin gene. However, this drug will not generate significant revenue given the small size of the targeted patient population.

  • There is no cure for cardiomyopathies, but the symptoms of the disease are managed with generic cardiovascular drugs. This remains an area of ​​unmet need in the cardiomyopathy field.

  • Camzyos was the first new therapy launched in the cardiomyopathy market for several decades when it was commercialized in 2022. There is therefore a need for new therapies in this space, which should be met by the large pipeline.

Scope

  • Overview of cardiomyopathies, including epidemiology, disease etiology, and management.

  • Market revenue for leading cardiomyopathy drugs (including complementary off-label therapies used for metabolic benefits), annual cost of therapy, and forecasted sales for key late-stage pipeline drugs.

  • Key topics covered include assessment of current and developing therapies, unmet needs, current and future players, and market outlook for the US, 5EU, and Japan over the 10-year forecast period.

  • Pipeline analysis: new emerging trends in development and detailed analysis of late-stage drugs in development.

  • Analysis of the current and future competition in the global cardiomyopathy therapeutics market. In-depth review of key industry drivers, restraints and challenges.

Reasons to buy

The report will allow you to:

  • Develop and design your licensing and licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

  • Develop business strategies by understanding the trends shaping and driving the global Cardiomyopathy Therapies market.

  • Generate revenue by understanding the key trends, innovative products and technologies, market segments, and companies that are likely to impact the global cardiomyopathy market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Track global cardiomyopathy therapies market drug sales from 2021 to 2031.

  • Organize your sales and marketing efforts by identifying the categories and market segments that present the maximum opportunities for consolidations, investments and strategic partnerships.

Main topics covered:

1 Cardiomyopathies: summary

2 Presentation

3 Overview of the disease

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

4 Epidemiology

4.1 Context of the disease

4.1.1 Risk factors and comorbidities

4.2 Global and historical trends

4.3 Forecasting methodology

4.4 Cardiomyopathy Epidemiology Forecast (2021-2031)

4.5 Debate

5 Disease management

5.1 Overview of diagnosis and treatment

5.2 KOL Knowledge of Disease Management

6 Competitive evaluation

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Improvements in genetic testing and gene therapies

7.3 Curative rather than preventive treatment options

7.4 New drugs with specific targets

7.5 Appropriate diagnosis and treatment of patients with amyloid cardiomyopathy

8 R&D strategies

8.1 Overview

8.1.1 Label extension

8.1.2 Development of drugs with new targets

8.2 Clinical trial design

8.2.1 Quality of life parameters

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Assessment Analysis

10.1 Overview

10.2 Competitive Evaluation

11 current and future players

11.1 Overview

11.2 Transaction Trends

12 Market Outlook

13 Appendix

For more information about this Drug Pipelines report, visit https://www.researchandmarkets.com/r/51ty3v

Source: Global Data

]]>
Lessons learned from the modernization of the Air Force ILS-S logistics system https://adidastennishu.com/lessons-learned-from-the-modernization-of-the-air-force-ils-s-logistics-system/ Thu, 17 Nov 2022 22:20:05 +0000 https://adidastennishu.com/lessons-learned-from-the-modernization-of-the-air-force-ils-s-logistics-system/ The Air Force’s Commercial and Enterprise Systems (BES) directorate is no stranger to modernization. BES’s Integrated Logistics – Procurement (ILS-S) system has been in constant modernization since the early 1980s, when its main component, the standard commercial procurement system, moved from assembly code to COBOL. Since then, there have been several mainframe consolidations, two failed […]]]>

The Air Force’s Commercial and Enterprise Systems (BES) directorate is no stranger to modernization. BES’s Integrated Logistics – Procurement (ILS-S) system has been in constant modernization since the early 1980s, when its main component, the standard commercial procurement system, moved from assembly code to COBOL. Since then, there have been several mainframe consolidations, two failed attempts to implement an enterprise resource planning system, and multiple attempts to better streamline and integrate…

READ MORE

The Air Force’s Commercial and Enterprise Systems (BES) directorate is no stranger to modernization. BES’s Integrated Logistics – Procurement (ILS-S) system has been in constant modernization since the early 1980s, when its main component, the standard commercial procurement system, moved from assembly code to COBOL. Since then, it has gone through several mainframe consolidations, two failed attempts to implement an enterprise resource planning system, and multiple attempts to better streamline and integrate its various moving parts and processes. More recently, BES moved the system to the cloud, specifically Amazon Web Services’ Cloud One.

Along the way, BES has learned a number of lessons learned about major system upgrades.

“Any time you change your entire infrastructure, it’s basically a base release. I mean, it’s not a minor release, it’s not a patch,” said James Harbison, ILS-S Principal Engineer for BES. “It’s a basic version. So we had to test our entire code base. »

Harbison said BES needed to break down all the functionality of ILS-S, write test descriptions, and then decide what would be automated and what would be manual. The most critical functions, he said, were the best candidates for automated testing. They ended up with around 10,000 automated scripts running continuously. Harbison credited this continuous testing for the reason the commissioning was nearly error-free.

Another important thing to remember was the need to avoid range drift; Harbison said trying to do too much at once has been the downfall of Air Force projects in the past. The problem with too many changes at once, he said, is that when you run a test and get a different output, you don’t know what change caused it.

Harbison also praised the decision to use open source code rather than an off-the-shelf commercial solution. He said that 95% of the ILS-S system code is open source.

“The only thing we have in our system that isn’t open source is the Oracle Relational Database, which is a COTS product,” Harbison said. “Because if you’re not careful, you’ll get a software stack you can’t afford. You’ll be doing all that work and coding, but you’ll be spending all your money on software licenses.

BES discovered that the open source version of Java is a fully functional third-generation language that does everything it needs. The application server and Big Data solution of ILS-S are also open source.

Harbison said one of the advantages of using open source solutions over COTS is the advantage of having a community of thousands of developers maintaining the code, as long as you stick to the big products rather than to niche products. And if something goes down, BES has a support contractor to fall back on because they have access to the source code.

Another benefit of open source solutions is the ability to break down code and examine what’s inside. Harbison said people often cite the possibility of vulnerabilities in open source code as a reason for choosing COTS products instead, but what they don’t consider is that those COTS products also depend on open source code. . It’s just not economical to code every line from scratch. But that same open-source community that maintains the code also makes it more likely that, if there is a vulnerability, someone will find it and report it before anyone can exploit it.

This combination of community maintenance and integrated threat information sharing is something that many have struggled to foster between the public and private sectors.

“In COTS, sometimes you just don’t know you have a threat because they won’t share code with you,” Harbison said. “But trust me, they’re also full of open source; they just won’t tell you.

Harbison cautioned, however, that this approach forces developers to stay on top of the latest releases in order to stay up-to-date on security patches. It can be a challenge.

He also cautioned against overestimating the cost savings of moving to the cloud. Some people have predicted that the cloud will be 10% of the cost of using the Defense Information Systems Agency’s mid-tier servers, but Harbison said it’s closer to half the cost. That said, he said BES saved about $22 million by getting rid of Unisys mainframes. Earlier this year, Harbison said, they also implemented reserve instances, which is on track to reduce costs even further, to somewhere between $2 million and $3 million.

Embracing agile development principles has also paid off, Harbison said. Prior to making this change, BES was shipping about 10 releases per year on the waterfall method. Since switching to Agile in 2018, Harbison said BES has increased the rate of releases to one per month.

Harbison then said that BES was looking to replicate its successes in modernizing ILS-S – which is the Air Force’s retail supply system – on its inventory control system, which is the supply of big.

“Basically, we’re going to move them out of an IBM mainframe, we’re going to move them to the cloud at the same time, because that’s the requirement. And it’s a four to five year effort, but we’re going to use the same kind of concept,” he said. “We do a lot of automated testing. So we use the same basic constructs, and everything for this parallel effort.

]]>
Vislink Announces Distribution of Series A Preferred Shares to Holders of Its Common Shares https://adidastennishu.com/vislink-announces-distribution-of-series-a-preferred-shares-to-holders-of-its-common-shares/ Wed, 09 Nov 2022 14:40:05 +0000 https://adidastennishu.com/vislink-announces-distribution-of-series-a-preferred-shares-to-holders-of-its-common-shares/ Mount Olive, New Jersey., November 09, 2022 (GLOBE NEWSWIRE) — Vislink Technologies, Inc.(NASDAQ:VISL) (“Vislink” or the “Company”), a global technology leader in the capture, delivery and management of high-quality live video and associated data in the media and entertainment, Law Enforcement and Defense, today announced that from November 9, 2022its Board of Directors has declared […]]]>

Mount Olive, New Jersey., November 09, 2022 (GLOBE NEWSWIRE) — Vislink Technologies, Inc.(NASDAQ:VISL) (“Vislink” or the “Company”), a global technology leader in the capture, delivery and management of high-quality live video and associated data in the media and entertainment, Law Enforcement and Defense, today announced that from November 9, 2022its Board of Directors has declared a dividend of one thousandth of a newly designated Series A Preferred Share, par value $0.00001 per share, for each outstanding share of the ordinary shares of the Company entered in the register at 5:00 p.m. Eastern Time on November 21, 2022. The Series A Preferred Shares are expected to be distributed to such beneficiaries at 5:00 p.m. Eastern Time on November 22, 2022. The outstanding Series A Preferred Shares will vote with the outstanding common shares of the Company, as a single class, exclusively with respect to a stock consolidation, and will not be entitled to vote on any other matter. , except to the extent required under the general corporate law of Delaware. Subject to certain limitations, each outstanding Series A Preferred Share will have 1,000,000 votes per share (or 1,000 votes per thousandth of a Series A Preferred Share).

All Series A Preferred Shares which are not present in person or by proxy at the meeting of shareholders called to vote on the Share Consolidation immediately before the opening of the votes at such meeting will be automatically redeemed by the Company. All outstanding Series A Preferred Shares which have not been so redeemed will be redeemed if such redemption is ordered by the board of directors of the Company or automatically upon approval by the shareholders of the Company of a amendment to the certificate of incorporation of the Company effecting the repurchase of divided shares at such meeting.

The Series A Preferred Shares will not be certified and no Series A Preferred Shares will be transferable by any holder thereof except in connection with a transfer by such holder of common shares of the Company held by such holder. . In such event, a one-thousandth number of Series A Preferred Shares equal to the number of common shares of the Company to be transferred by such holder would be transferred to the transferee of such common shares.

Additional details regarding the Series A Preferred Shares will be contained in a report on Form 8-K to be filed by the Company with the Security and Exchange Commission (“SECOND”).

Further details regarding a special meeting of shareholders of the Company to consider a stock consolidation should be contained in a definitive proxy statement at Schedule 14A which will be filed by the Company with the SECOND. This special meeting will be separate and distinct from the company’s previously announced 2022 annual meeting of shareholders, which is scheduled to be held on December 27, 2022. The special meeting will only relate to a proposal to possibly carry out a consolidation of shares. Series A Preferred Shares will not be eligible to participate in the 2022 Annual Meeting.

This communication does not constitute a solicitation of a vote or approval of any matter. Investors will be able to obtain a free copy of the definitive proxy statement for the 2022 separate annual and special meetings, when available, and other relevant documents filed by Vislink with the SECOND on the SEC’s website at www.sec.gov. In addition, investors may obtain a free copy of the applicable proxy statement, when available, and other relevant documents on Vislink’s website at www.vislink.com or by sending a ask Vislink Technologies, Inc.Attention: Secretary General, 350 Clark Drive, Mount Olive, New Jersey 07828, or by calling (908) 852-3700.

About Vislink TechnologiesInc. Vislink is a global technology company specializing in the collection, delivery and management of high-quality live video and associated data, from the action scene to the viewing screen. For broadcast markets, Vislink provides solutions for collecting live news, sports and entertainment events. Vislink also provides the surveillance and defense markets with real-time video intelligence solutions using a variety of bespoke transmission products. Through its Mobile Viewpoint product lines, Vislink also provides live streaming solutions using bonded cellular, 5G and AI-based technologies for automated news and sports productions.

The Vislink The team also provides professional and technical services using a team of technology experts with decades of applied knowledge and real-world experience in terrestrial microwave, satellite, fiber optic, surveillance and wireless communications, to provide a wide range of customer solutions. . Vislink’s common stock is publicly traded on the Nasdaq Capital Market under the symbol “VISL”. For more information, visit www.vislink.com.

Forward-looking statements:

Certain statements contained in this press release are forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor under the Private Securities Litigation Reform Act of 1995. This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical facts included in this press release, including those regarding a possible consolidation of the common stock , the Company’s strategy, future operations, future financial condition, future revenues, including from booking activity, risks of supply chain constraints and inflationary pressures, projected expenditures, outlook, plans, including consolidation of footprint and technology assets , management objectives, new capabilities, product and solution launches including AI-enabled and 5G streaming technologies, expect contract values, projected pipeline sales opportunities, integration of acquisitions and expected market opportunities in the Company’s operating segments, including the live event production market, the effects of the COVID-19 pandemic, the sufficiency of the Company’s capital resources to fund company operations and all statements regarding future results are forward-looking statements. Vislink may not actually achieve the plans, achieve the intentions or meet the expectations or projections disclosed in forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are based on management’s current expectations and involve risks and uncertainties, including those discussed in Vislink’s Annual Report on Form 10-K for the fiscal year ended. December 31, 2021filed with the SECOND on April 15, 2021as amended on May 2, 2022 and September 21, 2022and in documents subsequently filed with the SECOND.

Statements made in this press release speak only as of the date stated herein, and subsequent events and developments may cause the Company’s expectations and beliefs to change. Although the Company may elect to update these forward-looking statements publicly at some time in the future, the Company specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise, except if required by law. These forward-looking statements should not be taken to represent the views of the Company as of any date after the date set forth herein.

contacts

Media Relations:Charlotte van HertumCharlotte.vanhertum@vislink.com

Investor Relations:
investors@vislink.com

main logo

Source: Vislink Technologies, Inc.

2022 GlobeNewswire, Inc., source Press Releases

]]>
OraSure Technologies Receives Blanket Clearance for its ORAcollect®•Dx Device for Over-the-Counter (OTC) Use from the U.S. Food and Drug Administration (FDA) https://adidastennishu.com/orasure-technologies-receives-blanket-clearance-for-its-oracollectdx-device-for-over-the-counter-otc-use-from-the-u-s-food-and-drug-administration-fda/ Thu, 03 Nov 2022 13:16:03 +0000 https://adidastennishu.com/orasure-technologies-receives-blanket-clearance-for-its-oracollectdx-device-for-over-the-counter-otc-use-from-the-u-s-food-and-drug-administration-fda/ FDA clearance obtained through partnership with Grifols to support alpha risk screening1– Antripsyn (Alpha-1) deficiency in the US adult population BETHLEHEM, Pa., Nov. 03, 2022 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home specimen collection and diagnostic testing technologies, announced today that the company received US FDA clearance […]]]>

FDA clearance obtained through partnership with Grifols to support alpha risk screening1– Antripsyn (Alpha-1) deficiency in the US adult population

BETHLEHEM, Pa., Nov. 03, 2022 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home specimen collection and diagnostic testing technologies, announced today that the company received US FDA clearance for its ORAcollect®•Dx saliva collection device for over-the-counter (ie direct-to-consumer) use. The device had previously been cleared for prescription use by the FDA. ORAcollect®•Dx joins the Oragene®•Dx product line that previously received FDA blanket clearance for prescription and over-the-counter use. This new designation now allows ORAcollect®•Dx devices to be used by OraSure’s commercial partners and legally marketed with their therapeutics or devices in conjunction with their intended product use. The ORAcollect®•Dx and Oragene®•Dx devices are designed to be used by an adult at home, without the advice of a healthcare professional.

OraSure has received this designation through its partnership with Grifols to support screening for alpha1-antitrypsin (alpha-1) deficiency in individuals who may be at risk for alpha-1. Alpha-1 increases the risk of lung disorders in patients and it is estimated that approximately 3% of COPD patients have alpha-1. Starting Q2 2023, Grifols will offer the free AlphaID™ At Home Genetic Health Risk service, supporting alpha-1 screening, which uses the ORAcollect®•Dx device to help identify those at risk. According to the Centers for Disease Control, COPD affects more than 15 million people in the United States.

“This clearance represents a major milestone for OraSure as we work collaboratively with our business partners to increase access to healthcare,” said Kathleen Weber, President of Molecular Solutions for OraSure Technologies. “With the movement towards precision medicine, we increasingly see the need for genetic testing to support FDA-approved therapies as drugs become more specialized for targeted patient populations. This expanded designation now allows us to better support our customers and expands the potential for future indications with the ORAcollect®•Dx device.

“We look forward to working with an experienced partner like OraSure to expand access to alpha-1 testing and awareness,” said Antonio Martínez, president of Grifols Diagnostics.

About Genotek DNA
DNA Genotek Inc., a subsidiary of OraSure Technologies, Inc., is focused on providing high quality biological sample collection products and end-to-end services for human genomics and microbiome applications. The Company’s Oragene®•Dx and ORAcollect®•Dx product lines are the first and only FDA 510(k)-cleared saliva-based DNA collection devices for in vitro diagnostic use. DNA Genotek also offers research-only products for collecting and storing large amounts of DNA or RNA from several sample types. DNA Genotek markets its products worldwide and has a global customer base with thousands of customers in over 100 countries. For more information about DNA Genotek, visit www.dnagenotek.com.

About OraSure Technologies
OraSure Technologies enables the global community to improve health and well-being by providing access to accurate and essential information. OraSure, with its wholly owned subsidiaries, DNA Genotek, Diversigen and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture and distribution of rapid diagnostic tests, sample collection and stabilization devices and molecular service solutions designed to discover and detect critical medical conditions. OraSure’s product portfolio is sold worldwide to clinical laboratories, hospitals, medical practices, clinics, public health and community organizations, research institutes, government agencies, pharmaceutical companies, commercial entities and directly to consumers. For more information about OraSure Technologies, please visit www.orasure.com.

Important Information
This press release contains certain forward-looking statements, including with respect to the Company’s products, product development activities, regulatory submissions and clearances and other matters. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to differ materially from those expressed or implied by such statements include, but are not limited to: the risk that the Company’s exploration of strategic alternatives will not result in any definitive transaction or enhance shareholder value and may create distraction or uncertainty that could adversely affect results of operations, business or investor perception; the diversion of management’s attention from the company’s day-to-day operations and regular business responsibilities due to the company’s exploration of strategic alternatives; ability to solve the company’s ongoing manufacturing challenges and meet customer demand; ability to market and sell products, whether through our internal direct sales force or third parties; the impact of significant customer concentration in the genomics industry; failure of distributors or other customers to meet purchase forecasts, historical purchase levels or minimum purchase requirements for our products; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; the ability to obtain, and the timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations, and other findings or comments from the United States Food and Drug Administration (“FDA”) or other regulatory agencies; the impact of the novel coronavirus (“COVID-19”) pandemic on the Company’s business and its ability to successfully develop new products, validate the expanded use of existing collection products, receive approvals and necessary regulatory authorizations and to market these products for COVID-19 testing; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners to perform critical activities under collaborative arrangements; ability to meet increased demand for the Company’s products; impact of replacing distributors; inventory levels at distributors and other customers; the Company’s ability to achieve its financial and strategic objectives and to continue to increase its revenues, including the ability to expand its international sales; the impact of competitors, competing products and technological changes; reduction or postponement of public funding available to customers; competition from new or improved technologies or lower cost products; ability to develop, market and market new products; market acceptance of saliva or urine tests, swabs or other products; market acceptance and adoption of microbiome informatics, microbial genetics technology and related analytical services; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms, or other recommendations by the Centers for Disease Control and Prevention (“ CDC”) or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain distribution channels for new or existing products; dependence on single sources of supply for critical products and components; the availability of related products manufactured by third parties or products necessary for the use of our products; the impact of US government contracts; impact of negative economic conditions; ability to maintain sustained profitability; ability to utilize net operating losses carried forward or other deferred tax assets; the volatility of the price of the Company’s shares; uncertainty relating to patent protection and potential patent infringement claims; the uncertainty and costs of litigation relating to patents and other intellectual property rights; availability of patent or other technology licenses; ability to enter into international manufacturing agreements; barriers to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or depreciation of capital sources; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer groupings and inventory practices; equipment failures and the ability to obtain necessary raw materials and components; the impact of terrorist attacks and civil unrest; and general political, commercial and economic conditions. These and other factors that could affect our results are discussed in more detail in our filings with the SEC, including our registration statements, our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, our quarterly reports on Form 10-Q and other documents. with the SEC. Although forward-looking statements help provide information about future prospects, readers should be aware that forward-looking statements may not be relied upon. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no obligation to update such statements.

Investor contacts: Media Contact:
Scott Gleson Amy Koch
SVP Investor Relations and Corporate Communications Sr Msgr. Business communication
484-425-0588 484-523-1815
sgleason@orasure.com media@orasure.com

]]>
Bitcoin Price Prediction – This Is Where BTC Will Reach Before 2023! https://adidastennishu.com/bitcoin-price-prediction-this-is-where-btc-will-reach-before-2023/ Sun, 30 Oct 2022 13:33:53 +0000 https://adidastennishu.com/bitcoin-price-prediction-this-is-where-btc-will-reach-before-2023/ The crypto market has finally made its way to the top. Over the past week, most cryptos have risen by an average of 8% while the market capitalization of cryptos has crossed the $1 trillion mark. Bitcoin specifically managed to finally break through its psychological price of $20,000. Where will Bitcoin reach before 2023? Let’s […]]]>

The crypto market has finally made its way to the top. Over the past week, most cryptos have risen by an average of 8% while the market capitalization of cryptos has crossed the $1 trillion mark. Bitcoin specifically managed to finally break through its psychological price of $20,000. Where will Bitcoin reach before 2023? Let’s evaluate in this conservative Bitcoin price forecast.

Bitcoin Price Up 8% – What Happened?

A few positive events happened in the past week which pushed Bitcoin prices higher. After prolonged consolidations, prices are bound to rise when a bit of positive news surfaces. However, the events that happened were quite significant:

  • UK Approved Cryptos: Whenever a country (especially a powerful country) recognizes cryptocurrencies, it’s a big deal for the crypto market. In effect, it reassures investors that they are investing in a “legitimate investment” and that they are not at risk of losing everything they have invested.
  • Elon Musk bought Twitter: Elon is known to be a crypto enthusiast. While the platform has been officially acquired, the crypto community believes that Twitter would integrate NFTs or cryptocurrencies on its platform. This is likely because Binance was one of the investors that backed Elon in buying Twitter.
Bitcoin price prediction: BTC/USD 4-hour chart showing BTC price rising
Fig. 1 BTC/USD 4-Hour Chart Showing Rising BTC Price – GoCharting
exchange comparison

Bitcoin Price Prediction – Where Will Bitcoin Price Reach Before 2023?

If we look back to June, it took Bitcoin 1 month to rise $5,000 in its best case scenario. If we assume the same from November 1, 2022, we can notice that Bitcoin prices could reach between $25,000 and $30,000. This assumes that the crypto market continues to grow on a steady uptrend. However, adjustments could occur, bringing BTC prices back towards the bottom bracket.

In a post on LinkedIn, we asked the crypto community about their assumptions for BTC prices ahead of 2023. The results were mixed, but 60% assumed that Bitcoin prices would remain in consolidation between $18,000 and $22,000. They mainly predicted price adjustments that would lower BTC prices.

–> CLICK HERE TO FOLLOW US ON LINKEDIN <–

Will Bitcoin crash before 2023?

A bitcoin crash is a big word for bitcoin right now. There is no apparent reason for an accident. On the contrary, prices should increase. The worst case scenario would be another consolidation around the current price of $21,000. This means that if you wanted to get back on board, you might want to do so before the market rises further. However, remember to place your stop-loss triggers to avoid any losses in case the market turns sour.

BTC/USD 1-day chart showing potential Bitcoin price prediction
Fig.2 BTC/USD 1-day chart showing potential Bitcoin price prediction – GoCharting

Recommended posts


you might also like


More Bitcoin News

BREAKING: UK Endorses Crypto – Will Bullrun Return?

News has surfaced that the UK is endorsing cryptos. How will this affect crypto prices? Will investors return to their crypto…

Bitcoin or stocks – Where to invest your money TODAY?

In this article, we look at the pros and cons of Bitcoin and stocks, and the types of investors…

Bitcoin Price Prediction – BTC Entering Strong Buy Zone?

BTC prices fluctuated between $24,000 and $18,500. Is Bitcoin a good buy right now? Let’s analyze in this Bitcoin price prediction…

]]>
Acquisition of Apple Hospitality REIT – GuruFocus.com https://adidastennishu.com/acquisition-of-apple-hospitality-reit-gurufocus-com/ Thu, 27 Oct 2022 03:01:52 +0000 https://adidastennishu.com/acquisition-of-apple-hospitality-reit-gurufocus-com/ Apple Hospitality REIT, Inc. (NYSE: APLE) (the “Company” or “Apple Hospitality”) today announced the acquisition of AC Hotel by Marriott Louisville Downtown for $51 million, or approximately $327,000 per key, and the AC Hotel by Marriott Pittsburgh Downtown for $34 million, or approximately $254,000 per key. “We are delighted to enrich our portfolio with these […]]]>

Apple Hospitality REIT, Inc. (NYSE: APLE) (the “Company” or “Apple Hospitality”) today announced the acquisition of AC Hotel by Marriott Louisville Downtown for $51 million, or approximately $327,000 per key, and the AC Hotel by Marriott Pittsburgh Downtown for $34 million, or approximately $254,000 per key.

“We are delighted to enrich our portfolio with these attractive acquisitions which highlight the strength of our relationships with top hotel owner-operators and our ability to create value in a highly competitive market,” said Nelson Knight. , President, Real Estate. and Apple Hospitality investments. “These carefully designed hotels offer guests modern accommodations, comfortable meeting spaces and distinctive lounges, and are well positioned in their markets to benefit from a variety of business and leisure demand drivers. We continue to actively explore other opportunities, such as these, that will optimize our portfolio in ways that will enhance our future performance and maximize long-term value for our shareholders.

The 156-room AC Hotel Louisville Downtown opened in April 2018 and is located at 727 East Market Street, Louisville, Kentucky, in the bustling East Market district, also known as NuLu for New Louisville, which is home to upscale restaurants, boutiques, art galleries and entertainment venues. The hotel benefits from a variety of leisure, academic and sports demand generators given its proximity to the KFC Yum! Center, the University of Louisville, the Kentucky International Convention Center, well-known bourbon distilleries, various outdoor spaces and parks, and Churchill Downs, home of the annual Kentucky Derby. In addition, many large businesses and industries related to shipping and logistics, food and beverage, automobile manufacturing, healthcare and health insurance, among others, are located in Louisville and lead to business trips to the region. Recent hotel performance in Louisville has returned to pre-pandemic levels. According to data provided by STR for the month of September 2022 compared to September 2019, revenue per available room (“RevPAR”) for the Louisville CBD, KY submarket improved by approximately 2% and the RevPAR of AC Hotel Louisville Downtown improved by approximately 8%.

The 134-room AC Hotel Pittsburgh Downtown opened in July 2018 and is located at 1126 Smallman Street, Pittsburgh, Pennsylvania, next to the David L. Lawrence Convention Center and close to many restaurants, shops, art galleries , theatres, parks and riverside walks. trails of downtown Pittsburgh’s cultural district, Market Square and the Strip district. The hotel is conveniently located a short distance from the PPG Paints Arena, Acrisure Stadium and PNC Park, home to Pittsburgh’s professional sports teams and major leisure travel engines in the area. In addition to leisure demand drivers, the hotel benefits from a variety of business and academic demands driven by technology, robotics, financial services, manufacturing, automotive, and healthcare businesses located in the area as well as the University of Pittsburgh and Carnegie Mellon University. In recent months, Pittsburgh has seen hotel performance surpass pre-pandemic levels, and according to data provided by STR for the month of September 2022 compared to September 2019, the RevPAR of the Pittsburgh CBD, PA submarket improved by approximately 17% and RevPAR for the AC Hotel Pittsburgh Downtown improved by approximately 36%.

Following these acquisitions, the Apple Hospitality portfolio includes 220 hotels with 28,983 rooms geographically distributed in 37 states.

About Apple Hospitality REIT, Inc.

Apple Hospitality REIT, Inc. (NYSE: APLE) is a publicly traded real estate investment trust (“REIT”) that owns one of the largest and most diversified portfolios of upscale, room-based hotel properties. United States. Apple Hospitality’s portfolio consists of 220 hotels with approximately 29,000 rooms located in 87 markets across 37 states. A concentrate of industry-leading brands, the Company’s portfolio consists of 96 Marriott-branded hotels, 119 Hilton-branded hotels, four Hyatt-branded hotels and one independent hotel. For more information, visit www.applehospitalityreit.com.

Disclaimer of Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are generally identified by the use of statements that include expressions such as “may”, “believe”, “expect”, “anticipate”, “intend”, “estimate”, “project”, “target”, “goal”. ”, “plan”, “should”, “will”, “predict”, “potential”, “outlook”, “strategy” and similar expressions that convey uncertainty of future events or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such statements. forward-looking statements.

Currently, one of the most important factors that could cause actual results to differ materially from the company’s forward-looking statements continues to be the adverse effect of COVID-19, including resurgences and variations, on the company’s activities, financial performance and condition, its operations, results and cash flows, the real estate market and the hotel industry in particular, and the global economy and financial markets in general. The significance, extent and duration of the continued impacts caused by the COVID-19 pandemic on the Company will depend on future developments, which are highly uncertain and cannot be predicted with certainty at this time, including the extent, severity and duration of the pandemic. , the extent and effectiveness of the measures taken to contain the pandemic or mitigate its impact, the effectiveness, acceptance and availability of vaccines, the duration of associated immunity and the effectiveness of vaccines against variants of COVID-19, the potential for additional hotel closures/consolidations which may be mandatory or desirable, whether based on increasing COVID-19 cases, new variants or other factors, slowdown or potential cancellation of “reopenings” in some states, and the direct and indirect economic effects of the pandemic and containment measures, among others. In addition, investors are cautioned to interpret many of the risks identified in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as being heightened due to numerous and ongoing adverse effects of COVID-19. Additional factors include, but are not limited to, the Company’s ability to effectively acquire and sell properties and redeploy proceeds; the expected timing and frequency of distributions to shareholders; the Company’s ability to fund its capital obligations; the Company’s ability to successfully integrate ongoing operations and implement its operational strategy; changes in general political, economic and competitive conditions and specific market conditions; reduced business and leisure travel due to travel-related health concerns, including the COVID-19 pandemic or an increase in cases of COVID-19 or any other infectious or contagious disease in or around the United States abroad; adverse changes in real estate and real estate capital markets; funding risks; changes in interest rates; litigation risks; regulatory proceedings or investigations; and changes in applicable laws or regulations or interpretations of applicable laws and regulations that affect the Company’s business, assets or classification as a REIT. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of these assumptions may prove to be incorrect and, accordingly, there can be no assurance that such statements included in this press release will prove to be accurate. In light of the material uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be taken as a representation by the Company or any other person that the results or conditions described in such statements or the objectives and Company plans will be achieved. Furthermore, the qualification of the Company as a REIT involves the application of very technical and complex provisions of the Tax Code of 1986, as amended. Readers should carefully review the risk factors described in the company’s filings with the Securities and Exchange Commission, including, but not limited to, those discussed in the section entitled “Risk Factors” in the annual report. of the company on Form 10-K for the fiscal year ending December. 31, 2021. Any forward-looking statements made by the Company speak only as of the date of this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements or cautionary statements, as a result of new information, future events or otherwise, except as required by law.

For more information or to receive press releases by email, visit www.applehospitalityreit.com.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20221026005657/en/

]]>
Current trade update for the period from July 1, 2022 to September 30, 2022 https://adidastennishu.com/current-trade-update-for-the-period-from-july-1-2022-to-september-30-2022/ Wed, 19 Oct 2022 06:26:04 +0000 https://adidastennishu.com/current-trade-update-for-the-period-from-july-1-2022-to-september-30-2022/ Company Announcement No. 35 -2022 OrderYOYO A/SInside information Copenhagen, October 19, 2022 Strong points Good performance in Q3 2022 with a TAR of 185 million Danish kroner growing by 25% compared to the consolidated proforma figures for the third quarter of 2021. Despite difficult market conditions, OrderYOYO continues to gain market share in all major […]]]>

Company Announcement No. 35 -2022

OrderYOYO A/S
Inside information

Copenhagen, October 19, 2022

Strong points

Good performance in Q3 2022 with a TAR of 185 million Danish kroner growing by 25% compared to the consolidated proforma figures for the third quarter of 2021. Despite difficult market conditions, OrderYOYO continues to gain market share in all major markets, with our objective being to Liberate the restaurants become increasingly important and valuable to our Restaurant partners

Continued focus on profitability leads to positive EBITDA in Q3 22 of 1.9 million Danish kroner

Merger with smart app progressing as planned with realization of expected benefits – Growth Marketing cross-selling in German market improving our Restaurant partners (RP’s) digital sales and cross-selling of POS (Point of Sales) to UK the market is therefore ahead of the plan

December ARR Guidance Raised in Posted Announcement October 14 of DKK 180-195 million at DKK 185-200 million. Increase in EBITDA forecasts for the year 2022 October 19 of DKK (10)-0m at DKK (5)-0m as Q3 2022 showed positive EBITDA which is also expected for Q4

Release of 2023 forecast showing December ARR forecast of DKK 215-230 millionfull year 2023 net revenue forecast of DKK 190-205 million and positive EBITDA forecasts of DKK 5-15m

2023 thus continues our journey with a strong focus on profitability and balancing growth and profit in all the businesses we do, including market consolidations.

Financial Highlights

million DKK

Consolidated

Q3 2022

Q3 2021

Growth (%)

Annual recurring revenue (annualized September ARR- MRR)

185

148

25%

GMV (annualized September GMV)

1,868

1,702

ten%

Net revenue

45.1

40.5

11%

** Annualized September ART of 185 million Danish kroner versus. 148 million Danish crowns September 2021 (consolidated pro forma) corresponding to a growth of 25%

** Q3 net revenue of DKK 45.1 million versus. 40.5 million Danish kroner in Q3 2021 (consolidated pro forma) corresponding to growth of 11%

** Annualized September GMV of DKK 1,868 million versus. DKK 1,702 million in September 2021 (consolidated proforma) corresponding to a growth of 10%

** Positive EBITDA before other external costs for Q3 2022 of 1.9 million Danish kroner

Merger with app smart is developing as expected

** The OrderYOYO and smart app combination announced at the end of the first half of 2022 creates the largest restaurant liberator in Europe serving nearly 10,000 Restaurant partners. The merger is the first step toward the combined company’s overall goal of releasing more than 25,000 Restaurant partners by the end of 2025

** The combination of two market leaders, extending the number of market leading positions in Europe from three to five created the European market leader from day one and OrderYOYO is now the market leader in the two largest takeaway markets in EuropeUK and Germany

** The integration of the two companies is proceeding as planned and all the expected benefits of the merger of the two companies have been proven. Both companies share the same vision, mission and approach to the market, and furthermore have proven to be a strong cultural complementarity. All the reasons for strong fusion improvements already experienced

** Cross-selling of Growth Marketing on the German market and cross-selling of POS on the UK market ahead of plan

Consolidated guidance for 2022 raised in guidance announcement October 14, 2022

As the merger with app smart progress has successfully consolidated, the guidelines have changed as follows:

** December 2022 The annualized ART forecast has been raised by DKK 180-195 million at DKK 185-200 million

** The forecast for EBITDA before other external costs for the year 2022 has changed from DKK (10)-0m at DKK (5)-0m

** December 2022 Full-Year 2022 Annualized GMV and Net Revenue Guidance Unchanged

million DKK

Tips

Running

Updated

December 2022 Recurring annual revenue

180-195

185-200

December 2022 Annualized GMV

2,050-2,200

2,050-2,200

Net turnover 2022

140-155

140-155

2022 EBITDA before other exceptional items

(10)-0

(5)-0

Publication of consolidated forecasts for 2023

As the merger between OrderYOYO and app smart has created a somewhat different company, the Board of Directors has decided to release a forecast for 2023 following the Q3 2022 Current Trade Update.

million DKK

Consolidated guidelines

FISCAL YEAR 2023

FISCAL YEAR 2022

Growth (%)

December 2023 Recurring annual income

215-230

185-200

15-16%

December 2023 Annualized GMV

2,200-2,400

2,050-2,200

7-9%

Net revenue*

190-205

140-155

32-36%

EBITDA

5-15

(5)-0

nm

*Fiscal year 2022 contains 6 months of app smart net revenue (July-December)

** December 2023 annualized ARR guidance of DKK 215-230 million corresponding to a growth of 15 to 16% compared to the current forecasts raised for 2022

** Positive EBITDA before other external costs Forecast for the year 2023 of DKK 5-15m

** Net sales forecast for the year 2023 of DKK 190-205 million corresponding to 32-36% growth from the current 2022 guidance. Adjusted for the full-year effect of pro forma net revenue growth pro forma from the 2023 application guided at 7-8%

** December 2023 annualized GMV guidance of DKK 2,200-2,400 million corresponding to a growth of 7 to 9% compared to the current forecast for 2022

For more information, please contact

OrderYOYO A/S

jesper johansenCEO

Mobile (+45) 21 67 84 92

Email jesper.johansen@orderyoyo.com

OrderYOYO A/S Masnedøgade 26, 2100 Copenhagen Ø

Certified Advisor

Grant Thorton

Jesper Skaarup Vestergaard

Mobile (+45) 31 79 90 00

Grant Thornton Stockholmsgade 45, 2100 Copenhagen Ø

About OrderYOYO

OrderYOYO is the leading European provider of online ordering, payment and marketing software solutions on the market. The OrderYOYO solution is offered as software as a service (SaaS) and enables small independent take-out restaurants to have their own online presence directly with consumers. OrderYOYO helps take-out restaurants manage online take-out orders through their own bespoke software solution under the individual take-out restaurant’s own brand. We liberate restaurants.

https://news.cision.com/orderyoyo-as/r/current-trading-update-for-the-period-july-1–2022—september-30–2022,c3650909

https://mb.cision.com/Public/20605/3650909/8c943de8f368acca.pdf

(c) Decision 2022. All rights reserved., sources Press Releases – English

]]>
Foundation sets a goal of $185,000 during its annual campaign | News, Sports, Jobs https://adidastennishu.com/foundation-sets-a-goal-of-185000-during-its-annual-campaign-news-sports-jobs/ Sun, 16 Oct 2022 06:22:30 +0000 https://adidastennishu.com/foundation-sets-a-goal-of-185000-during-its-annual-campaign-news-sports-jobs/ Front row are WMHF Executive Director Patricia Gaughan DiPalma, Kathryn Bronstein, PhD, WMHF President and Foundation Board Members Rose Van Volkenburg, Chris Adams, WMHF Treasurer, back row : Jon Northrop, WMHF Vice President, Dan Hockings, Shara Post and Colleen Meeder, WMHF Secretary, welcome guests to the AHN Westfield Memorial – 80 Years […]]]>

Front row are WMHF Executive Director Patricia Gaughan DiPalma, Kathryn Bronstein, PhD, WMHF President and Foundation Board Members Rose Van Volkenburg, Chris Adams, WMHF Treasurer, back row : Jon Northrop, WMHF Vice President, Dan Hockings, Shara Post and Colleen Meeder, WMHF Secretary, welcome guests to the AHN Westfield Memorial – 80 Years of ‘Scaling Up’ event for our community.

The Westfield Memorial Hospital Foundation announces that its 2022 annual campaign is now underway with a goal of $185,000, according to Dr. Kathryn Bronstein, chair of the board.

As a major fundraising source for AHN Westfield Memorial, the WMH Foundation works with the community hospital to provide financial support for the delivery of high quality health care to residents of Chautauqua County and beyond.

In the past year alone, the Foundation has funded eight new state-of-the-art hospital beds, the installation of a new television system throughout the hospital, and kitchen supplies for the revitalized hospital kitchen.

WMHF Executive Director Patricia Gaughan DiPalma said: “The entire Foundation Board of Directors and I are pleased to inform you that we have reached the fundraising goal of last year’s annual campaign thanks to our kind and generous donors! We couldn’t have done it without all of you! That said, we continue to need your help to deliver on our promises.

“If WMH is to remain a forerunner in improved diagnostic services, the Foundation will be called upon repeatedly to fund the sophisticated equipment needed to modernize all hospital services,” DiPalma observed.

With this in mind, Dr. Bronstein noted, “We would like to see more residents participating in this campaign than ever before. It’s the generosity of the people the hospital serves that helps make the difference. I challenge everyone in our hospital service area of ​​Ashville, Bemus Point, Brocton, Chautauqua, Clymer, Dewittville, Findley Lake, Mayville, Panama, Portland, Ripley, Sherman, Stockton and Westfield to step up and take ownership the need for state-of-the-art medical equipment for our community hospital.

Every dollar is vital for the Foundation’s annual campaign. “If you appreciate having a hospital nearby, and if you, a friend, neighbor, family member or loved one have ever been a patient at AHN Westfield Memorial, please make a tax-deductible donation of any amount to our campaign,” says Bronstein. “Every donation is important to achieve our goal. Support your community hospital and send your donation today.

Bronstein also reflected on how the WMH Foundation recently helped organize the highly successful AHN Westfield Memorial – 80 Years of Stepping Up for Our Community event to celebrate the hospital’s anniversary and promote health within our community. community. It was a day of family fun, with gift baskets given away and a raffle with great prizes – all proceeds will benefit the AHN Westfield Memorial. The event also included a 5K walk, a magician, healthy cooking demonstrations and snacks, fire engines and a helicopter tour. Free critical health examinations were also available.

“As we emerge from a demanding three-year pandemic, this special day in September focused on the importance of this important milestone for our community hospital; it also strengthened the Foundation’s determination to fulfill its mission.

The added strains of the country’s large but fragmented healthcare system are even more pronounced in rural communities like ours and we recognize the importance of bringing in new services and funding state-of-the-art equipment,” Bronstein said.

“We are grateful to you and to the hospital’s many dedicated health care providers, associates, and the unwavering commitment of the hospital’s three volunteer board members over the past 80 years. “, she continued.

“In this era of hospital mergers and amalgamations, we are fortunate to have access to many services nearby and very much appreciate our affiliation with Alleghany Health Network,” remarked DiPalma.

A recent mailing to past and potential donors, noted that the Westfield Memorial Hospital Foundation is beginning this year’s annual campaign; we ask that you join this worthy cause by returning your donation by December 31 to the WMH Foundation located at 189 East Main Street, Westfield, NY.

For those interested in learning more about the Foundation or how to donate to the 2022 Annual Campaign, contact Ms. DiPalma at patricia.dipalma@ahn.org; call: 716-793-2338 or visit the Foundation’s website at: www.westfieldhospitalfoundation.org.

In addition to emergency care, the hospital offers a range of services, including outpatient and short-term surgery, outpatient diagnostic services, physiotherapy, cardiac testing and rehabilitation, imaging, diagnosis for women, digital mammography, lab, diabetes education, nuclear stress testing. , wound and infusion clinics, inpatient care and a suite of specialty services that includes general surgery, digestive diseases, OB-GYN services, orthopedics, urology, cardiology and diverse hearing services.

Telemedicine services for rheumatology and endocrinology are also available at AHN-WMH. The hospital also provides primary care services on the grounds of the Chautauqua facility during its nine-week summer season.



Today’s breaking news and more to your inbox







]]>
Essentia Health and Marshfield Clinic Health System discuss merger, tout ‘exciting opportunity’ https://adidastennishu.com/essentia-health-and-marshfield-clinic-health-system-discuss-merger-tout-exciting-opportunity/ Fri, 14 Oct 2022 04:20:11 +0000 https://adidastennishu.com/essentia-health-and-marshfield-clinic-health-system-discuss-merger-tout-exciting-opportunity/ If they agree to merge, a merger would produce a system with 25 hospitals and over 26,000 employees. The deal comes during a fairly slow period for hospital consolidations. Essentia Health and the Marshfield Clinic Health System have begun talks that could lead to a merger. The two health systems said this week they had […]]]>

If they agree to merge, a merger would produce a system with 25 hospitals and over 26,000 employees. The deal comes during a fairly slow period for hospital consolidations.

Essentia Health and the Marshfield Clinic Health System have begun talks that could lead to a merger.

The two health systems said this week they had signed a memorandum of understanding to explore how the two systems could come together to create a regional health system.

If Essentia and Marshfield Clinic merge, it would create a system of 25 hospitals and over 26,000 employees. The systems said in a statement that they could improve healthcare for patients and offer “complimentary geographies and capabilities.”

Essentia operates 14 hospitals as well as dozens of clinics in Minnesota and North Dakota, as well as a few locations in Wisconsin. Essentia employs over 14,000 people.

Marshield Clinic operates 11 hospitals and other care sites in the Upper Peninsula of Wisconsin and Michigan. The system employs over 12,000 workers.

The two organizations said the memorandum of understanding represents the first step towards a possible merger, but they did not share a timeline for future plans. Systems said more information would be released later.

Essentia CEO Dr. David Herman said he has respected the work of the Marshfield Clinic for decades.

“I have always appreciated their ability to advance the well-being of the communities they serve,” Herman said in a statement. “I am truly delighted to be working together for the benefit of our patients and our colleagues.”

The two organizations also share similar values, he said. “Through a new partnership, we can support models of care, services, research and technologies to ensure sustainable and thriving rural health care,” Herman said.

“This is an exciting opportunity for both our organizations and those we serve,” Marshfield Clinic Health System CEO Dr. Susan Turney said in a statement.

“These are two of the nation’s leading health systems, seeking to come together to serve rural communities and beyond,” she said. “When I look at Essentia, I see an organization with world-class expertise that complements ours. And I see their long and storied history of serving communities with a mission very similar to ours at Marshfield Clinic Health System.

The organizations said in a press release that a merger would provide expanded primary and specialty care opportunities for patients.

Essentia and Marshfield Clinic, while serving northern states, have little overlap in their service areas, which could reduce Federal Trade Commission approval issues.

The FTC recently objected to several agreements reached by hospital systems in overlapping areas, prompting the organizations to halt their merger plans. President Biden’s administration has ordered regulators to apply greater scrutiny to hospital mergers to avoid higher costs to consumers and reduced services.

The COVID-19 pandemic appears to have slowed the pace of hospital consolidations, analysts said. Many systems have been concerned about handling the pandemic, as well as labor shortages and supply chain issues.

In the third quarter of 2022, only 10 hospital transactions were announced, according to Kaufman Hall, a consulting firm that works with healthcare organizations. There were only 25 deals announced in the first half of the year. Although there were fewer transactions, transactions were larger, including the proposed merger of Atrium Health and Advocate Aurora Health.

Two agreements on the health system have just been announced last week.

LCMC Health has reached an agreement to purchase three New Orleans area hospitals from HCA Healthcare. Yale New Haven Health System plans to purchase two Connecticut health systems, including three hospitals, from Prospect Medical Holdings.

]]>
Warner Bros. TV lays off 82 employees in unscripted and animation areas https://adidastennishu.com/warner-bros-tv-lays-off-82-employees-in-unscripted-and-animation-areas/ Wed, 12 Oct 2022 01:45:21 +0000 https://adidastennishu.com/warner-bros-tv-lays-off-82-employees-in-unscripted-and-animation-areas/ Warner Bros. Television Group has laid off 82 employees in its unscripted and animation departments in another round of cuts at Warner Bros. Discovery. As Variety reported, the chairman of Warner Bros. TV Group, Channing Dungey, sent a memo to employees on October 11 announcing the layoffs. The memo also explained that the company would […]]]>

Warner Bros. Television Group has laid off 82 employees in its unscripted and animation departments in another round of cuts at Warner Bros. Discovery.


As Variety reported, the chairman of Warner Bros. TV Group, Channing Dungey, sent a memo to employees on October 11 announcing the layoffs. The memo also explained that the company would choose not to fill 43 vacant positions, resulting in a total loss of 125 jobs. This represents 26% of the total workforce of Warner Bros. TV Group.

RELATED: HBO Max Lawsuit Is Another Unforced Mistake For Warner Bros. Discovery

This news came shortly after Warner Bros. TV Group, which acts as the production arm for The CW and DC Comics as well as the distribution arm for Cartoon Network, Adult Swim and HBO, has elected to shut down Stage 13 and end Warner Bros. Television. Workshop. The layoffs include consolidations at Warner Bros. Unscripted Television. Warner Bros. Animation, Cartoon Network Studios and Hanna Barbera Studios will still exist, although Warner Bros. Animation and Cartoon Network Studios will merge their core development and production teams. According to reports, the Cartoon Network, Adult Swim, and HBO Max output will remain the same.

“These are challenging times in the world at large and a tumultuous time in our industry,” Dungey wrote in the memo. “For this type of change to hit so close to home is incredibly difficult. But I hope these changes, made in view of a more focused business strategy, will strengthen and stabilize our business, maintain our great creative output and better position us for continued future success.”

RELATED: Adult Swim Cuts Several Anime, Cartoons as Warner Bros. Discovery Purge grows

The announcement comes after reports that Warner Bros. Discovery was ready for another round of layoffs at the company. While it’s unclear exactly when the cuts will take place, insiders have reported that the layoffs will begin in October. “Everyone has been given financial goals for the fourth quarter… Those goals include the number of people, and October has always been the wait for the ax to fall,” an insider said.

The merger between Warner Bros. and Discovery in April resulted in several changes to the company, including layoffs, the removal of Warner Bros. of the streaming service and the cancellation of upcoming HBO Max exclusives like bat girl. However, the chairman and CEO of Warner Bros. Discovery’s David Zaslav has revealed plans to expand HBO Max’s content library as a whole, with a focus on increasing “content” and overall “quality.” It was also reported that the streaming service’s recent content purge has saved the company “tens of millions of dollars”.

HBO and HBO Max lost 70 employees, totaling 14% of their staff, in a wave of layoffs in August, including high-level executives. Other reports suggest the downsizing and restructuring are part of Zaslav’s effort to save $3 billion after the company’s net loss of $3.4 billion in the merger.

Source: Variety

]]>